Systematic Evaluation Of Renal Protection Of Liraglutide In Diabetic Patients

OBJECTIVE:To systematically evaluate the renal protective effect of Liraglutide in patients with diabetes mellitus(DM)and evaluate its efficacy and safety by using Meta-analysis method.Methods:Strict retrieval strategies and inclusion and exclusion criteria were established.Chinese and English databases,clinical trial registries and grey literatures were searched by computer.All Randomized Controlled trials(RCTs)that met the inclusion and exclusion criteria were screened out.Data were extracted independently by two investigators and the quality was evaluated.Finally,RevMan 5.3 and Stata15.1 statistical software were used for meta-analysis of relevant outcome indicators in the included literatures.RESULTS:A total of 26 literatures meeting the inclusion and exclusion criteria were included,including 22 literatures in Chinese and 4 literatures in English,and a total of 11514 patients were included,including 5754 cases in the observation group and 5760 cases in the control group.Results indicate:(1)than the control group,the lalu peptide group can more effectively reduce the DM patients’ urine trace albumin excretion rate,urine albumin creatinine ratio,serum creatinine,blood urea nitrogen,uric acid,fasting plasma glucose,postprandial 2 hours blood sugar,glycosylated hemoglobin,body mass index,total cholesterol,three acyl glycerin,tumor necrosis factor alpha and interleukin-6,P<0.05,the difference is statistically significant.(2)Compared with the control group,there were no significant differences in glomerular filtration rate,high-density lipoprotein and diastolic blood pressure in the liraglutide group.As for systolic blood pressure,due to the lack of robust combined effect size in various studies,it cannot be proved that the liraglutide group is superior to the control group in reducing systolic blood pressure at present.Larder sample size and higher quality RCT test results are needed.(3)Liraglutide had certain adverse reactions,mainly gastrointestinal reactions,the incidence of which was statistically significant compared with the statistical group;On the other hand,liraglutide had a significantly lower risk of hypoglycemic events than the control group.CONCLUSIONS:Liraglutide can effectively reduce urinary protein,inhibit inflammatory response,protect renal function,delay the occurrence and progression of diabetic kidney disease(DKD)in DM patients,and has good safety.However,due to the limitations of this study,higher quality RCT tests are needed in the future to provide more reliable evidence-based medicine.